Cancer-Retina Antigens in the Urine of Bladder and Prostate Cancer Patients

It has recently been shown that combination of arrestin and recoverin can serve as an effective urinary biomarker for renal cell carcinoma with sensitivity and specificity of over 92%. In this work, we studied the possibility of detecting these antigens in the urine in other urological oncological d...

Full description

Saved in:
Bibliographic Details
Published in:Biochemistry (Moscow) 2022-11, Vol.87 (11), p.1268-1276
Main Authors: Shlyapnikov, Yuri M., Malakhova, Ekaterina A., Vinarov, Andrey Z., Potoldykova, Natalia V., Vladimirov, Vasiliy I., Zernii, Evgeni Yu, Zamyatnin, Andrey A., Shlyapnikova, Elena A.
Format: Article
Language:English
Subjects:
Antigens
Antigens, Neoplasm
Arrestin
Arrestins
Biochemistry
Biomarkers
Biomarkers, Tumor
Biomedical and Life Sciences
Biomedicine
Bioorganic Chemistry
Bladder
Bladder cancer
Cancer patients
Genetic aspects
Humans
Identification and classification
Immunoassay
Kidney cancer
Life Sciences
Male
Microbiology
Patients
Properties
Prostate cancer
Prostatic Neoplasms - diagnosis
Recoverin
Renal cell carcinoma
Retina
Sensitivity
Sensitivity and Specificity
Tumors
Urinary Bladder
Urinary Bladder Neoplasms - diagnosis
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:It has recently been shown that combination of arrestin and recoverin can serve as an effective urinary biomarker for renal cell carcinoma with sensitivity and specificity of over 92%. In this work, we studied the possibility of detecting these antigens in the urine in other urological oncological diseases – bladder cancer (BC) and prostate cancer (PCa). Urine samples from 40 BC patients and 40 PCa patients were analyzed using an ultrasensitive microarray immunoassay with a detection limit of 0.1 pg/ml. It was shown that in BC the sensitivity of determining combination of arrestin with recoverin is 58% (AUC 0.76, 95% CI 0.66-0.86), while in PCa it is 60% (AUC 0.7, 95% CI 0.68-0.88). It has been established that in patients with bladder and prostate cancer who had a positive test, these antigens are not detected in 90% of cases after removal of the tumor. In the future, the obtained results could become the basis for developing new approaches for timely detection of relapses of such diseases and treatment control, as well as for the development of new diagnostic methods.
ISSN:0006-2979
1608-3040
DOI:10.1134/S0006297922110062